Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study - PubMed (original) (raw)
Randomized Controlled Trial
Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study
Mehmet Cindoruk et al. Helicobacter. 2007 Aug.
Abstract
Background: Recent studies indicate a potential role of Saccharomyces boulardii in the prevention of Helicobacter pylori treatment-related side-effects and also in improvement of eradication rate. Our aim is to investigate the efficacy and safety of S. boulardii in the prevention of side-effects related to H. pylori eradication. The secondary aim of the study was to define the effect of S. boulardii on the eradication success of anti-H. pylori therapy.
Materials and methods: One hundred and twenty-four patients with H. pylori infection (male/female: 44/80, mean age: 48 +/- 14.25 year) receiving 14 days of triple therapy (clarithromycin 500 mg b.i.d., amoxicillin 1000 mg b.i.d., and lansoprazole 30 mg b.i.d.) were randomly assigned to S. boulardii or placebo. Dyspeptic symptoms were recorded by using modified Glasgow Dyspepsia Questionnaire (GDQ). Side-effect profile and tolerability were assessed using a symptom-based questionnaire. H. pylori status was rechecked after 6 weeks after completion of eradication therapy.
Results: H. pylori eradication rate, although higher in the treatment group, was statistically similar in treatment and control groups: 71% (44/62) versus 59.7% (37/62), respectively (p > .05). Nine (14.5%) patients in the treatment group and 19 (30.6%) patients in the placebo group experienced diarrhea (p < .05). Epigastric discomfort was more frequent in the control group [9 (14.5%) versus 27 (43.5%), respectively (p < .01)]. Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups. GDQ scores after treatment were significantly better for treatment group (mean +/- SD, range: 1.38 +/- 1.25 (0-5) vs. 2.22 +/- 1.44 (0-6), respectively; p < .01).
Conclusion: S. boulardii improved anti-H. pylori antibiotherapy-associated diarrhea, epigastric discomfort, and treatment tolerability. In addition, S. boulardii supplement decreased post-treatment dyspepsia symptoms independent of H. pylori status. However, S. boulardii had no significant affect on the rate of H. pylori eradication.
Similar articles
- Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study.
Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A. Cremonini F, et al. Am J Gastroenterol. 2002 Nov;97(11):2744-9. doi: 10.1111/j.1572-0241.2002.07063.x. Am J Gastroenterol. 2002. PMID: 12425542 Clinical Trial. - Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.
Kim N, Park SH, Seo GS, Lee SW, Kim JW, Lee KJ, Shin WC, Kim TN, Park MI, Park JJ, Hong SJ, Shim KN, Kim SW, Shin YW, Chang YW, Chun HJ, Lee OJ, Jeon WJ, Park CG, Cho CM, Park CH, Won SY, Lee GH, Park KS, Shin JE, Kim HU, Park JY, Chae HS, Song GA, Kim JG, Yoon BC, Seol S, Jung HC, Chung IS. Kim N, et al. Helicobacter. 2008 Dec;13(6):542-9. doi: 10.1111/j.1523-5378.2008.00648.x. Helicobacter. 2008. PMID: 19166420 Clinical Trial. - Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia.
Froehlich F, Gonvers JJ, Wietlisbach V, Burnand B, Hildebrand P, Schneider C, Saraga E, Beglinger C, Vader JP; Eradication in Dyspepsia (ERADYS) Study Group. Froehlich F, et al. Am J Gastroenterol. 2001 Aug;96(8):2329-36. doi: 10.1111/j.1572-0241.2001.04037.x. Am J Gastroenterol. 2001. PMID: 11513170 Clinical Trial. - Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori.
Wilhelm SM, Johnson JL, Kale-Pradhan PB. Wilhelm SM, et al. Ann Pharmacother. 2011 Jul;45(7-8):960-6. doi: 10.1345/aph.1Q104. Epub 2011 Jun 21. Ann Pharmacother. 2011. PMID: 21693698 Review. - Probiotics in the prevention and treatment of gastrointestinal infections.
Huebner ES, Surawicz CM. Huebner ES, et al. Gastroenterol Clin North Am. 2006 Jun;35(2):355-65. doi: 10.1016/j.gtc.2006.03.005. Gastroenterol Clin North Am. 2006. PMID: 16880070 Review.
Cited by
- Saccharomyces boulardii in childhood.
Vandenplas Y, Brunser O, Szajewska H. Vandenplas Y, et al. Eur J Pediatr. 2009 Mar;168(3):253-65. doi: 10.1007/s00431-008-0879-7. Epub 2008 Dec 19. Eur J Pediatr. 2009. PMID: 19096876 Review. - Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.
Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC. Goldenberg JZ, et al. Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4. Cochrane Database Syst Rev. 2017. PMID: 29257353 Free PMC article. Review. - Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.
Seddik H, Boutallaka H, Elkoti I, Nejjari F, Berraida R, Berrag S, Loubaris K, Sentissi S, Benkirane A. Seddik H, et al. Eur J Clin Pharmacol. 2019 May;75(5):639-645. doi: 10.1007/s00228-019-02625-0. Epub 2019 Jan 29. Eur J Clin Pharmacol. 2019. PMID: 30694338 Clinical Trial. - Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis.
Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Lv Z, et al. Exp Ther Med. 2015 Mar;9(3):707-716. doi: 10.3892/etm.2015.2174. Epub 2015 Jan 9. Exp Ther Med. 2015. PMID: 25667617 Free PMC article. - A meta-analysis of probiotic efficacy for gastrointestinal diseases.
Ritchie ML, Romanuk TN. Ritchie ML, et al. PLoS One. 2012;7(4):e34938. doi: 10.1371/journal.pone.0034938. Epub 2012 Apr 18. PLoS One. 2012. PMID: 22529959 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical